Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...

Full description

Saved in:
Bibliographic Details
Published in:Intestinal research 2020, 18(4), , pp.355-378
Main Authors: Sood, Ajit, Ahuja, Vineet, Midha, Vandana, Sinha, Saroj Kant, Pai, C. Ganesh, Kedia, Saurabh, Mehta, Varun, Bopanna, Sawan, Abraham, Philip, Banerjee, Rupa, Bhatia, Shobna, Chakravartty, Karmabir, Dadhich, Sunil, Desai, Devendra, Dwivedi, Manisha, Goswami, Bhabhadev, Kaur, Kirandeep, Khosla, Rajeev, Kumar, Ajay, Mahajan, Ramit, Misra, S. P., Peddi, Kiran, Singh, Shivaram Prasad, Singh, Arshdeep
Format: Article
Language:English
Subjects:
5-aminosalicylic acid
colitis, ulcerative
crohn disease
inflammatory bowel disease
mesalamine
Review
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
ISSN:1598-9100
2288-1956
DOI:10.5217/ir.2019.09176